DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - DBV Technologies, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 27 Annual Global Investment Conference on September 9, 2025 [1] - The company is focused on developing treatment options for food allergies using its proprietary VIASKIN patch technology [3] Company Overview - DBV Technologies is headquartered in Châtillon, France, with operations in Warren, NJ, North America [4] - The company is dedicated to addressing significant unmet medical needs related to food allergies through epicutaneous immunotherapy (EPIT) [3] - The VIASKIN patch aims to desensitize individuals to allergens by leveraging the skin's immune properties [3] Clinical Focus - Current clinical trials include the VIASKIN Peanut for peanut allergic toddlers aged 1 to 3 years and children aged 4 to 7 years [3]